<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01110005</url>
  </required_header>
  <id_info>
    <org_study_id>32118</org_study_id>
    <nct_id>NCT01110005</nct_id>
  </id_info>
  <brief_title>A Trial of Intravenous Fluids During Labor</brief_title>
  <acronym>RARHY</acronym>
  <official_title>A Multi-Center, Two-Arm, Single-Blind Randomized Trial of IV Fluids During Labor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lehigh Valley Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Reading Hospital and Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Luke's Hospital, Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if intrapartum use of a glucose-containing solution
      will improve the outcomes in pregnant women and their babies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a multi-center, prospective, single-blind randomized trial of two types of IV
      fluids for maintenance hydration during labor. This study will be conducted at 4 sites:
      Reading (Reading Hospital), Allentown (Lehigh Valley), St. Luke Hospital and Hershey (Penn
      State College of Medicine). It will include 1524 pregnant women at ≥ 36 weeks presenting in
      spontaneous labor for anticipated delivery.

      The primary research hypothesis is that intravenous hydration during labor with a
      glucose-containing fluid will lead to more efficient uterine contractility and will lead to a
      reduction of cesarean delivery. The primary outcome measure is the occurrence of a cesarean
      birth during the study period. The primary analysis will use an intent-to-treat approach to
      examine differences between the two IV fluid treatments in the proportion of deliveries
      requiring cesarean section.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C-Section</measure>
    <time_frame>From onset of labor to delivery</time_frame>
    <description>Compare c-section rates between the D5LR and LR treatment groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxytocin Augmentation</measure>
    <time_frame>From onset of labor to delivery</time_frame>
    <description>Compare augmentation rates between the D5LR and LR treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Delivery</measure>
    <time_frame>From onset of labor to delivery</time_frame>
    <description>Compare time to delivery between the D5LR and LR treatment groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">318</enrollment>
  <condition>Ketosis</condition>
  <arm_group>
    <arm_group_label>D5 Lactated Ringer's solution (D5LR)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV fluid containing glucose administered throughout labor at an average infusion rate of 125 ml/hr.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactated Ringer's solution (LR)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-glucose IV fluid administered throughout labor at an average infusion rate of 125 ml/hr.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>D5 Lactated Ringer's Solution (D5LR)</intervention_name>
    <description>D5LR IV fluid</description>
    <arm_group_label>D5 Lactated Ringer's solution (D5LR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lactated Ringer's Solution (LR)</intervention_name>
    <description>LR IV fluid</description>
    <arm_group_label>Lactated Ringer's solution (LR)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women of any age with a singleton gestation in spontaneous labor at greater than or
             equal to 36 weeks without contraindication to participation.

          2. These women will be in good health and candidates for vaginal delivery.

        Exclusion Criteria:

          1. Patients who are not candidates for vaginal delivery. This may be due to fetal
             malpresentation, prior cesarean section, multiple gestations, etc.

          2. Patients presenting for induction of labor or requiring induction upon admission.

          3. Patients presenting for scheduled cesarean section.

          4. Patients with any form of diabetes or glucose dysregulation condition.

          5. Concurrent use of steroids.

          6. Patients presenting in active labor with advanced cervical dilation (≥ 6 cm).

          7. Subjects participating in another labor and delivery related clinical trial that
             conflicts with this trial (as determined by the site PI).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard S Legro, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, United States</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Smulian, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lehigh Valley Hospital, Allentown, Pennsylvania, United States</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lehigh Valley Hospital</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>17901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke Hospital</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Penn State University</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Reading Hospital and Medical Center</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2010</study_first_submitted>
  <study_first_submitted_qc>April 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2010</study_first_posted>
  <results_first_submitted>January 24, 2017</results_first_submitted>
  <results_first_submitted_qc>January 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 14, 2017</results_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Richard S. Legro, M.D.</investigator_full_name>
    <investigator_title>Professor, Obstetrics and Gynecology and Public Health Sciences</investigator_title>
  </responsible_party>
  <keyword>D5LR</keyword>
  <keyword>glucose containing IV solution</keyword>
  <keyword>LR</keyword>
  <keyword>non glucose IV solution</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>D5 Lactated Ringers Solution (D5LR)</title>
          <description>IV fluid containing glucose administered throughout labor at an average infusion rate of 125 ml/hr.</description>
        </group>
        <group group_id="P2">
          <title>Lactated Ringers Solution (LR)</title>
          <description>Non-glucose IV fluid administered throughout labor at an average infusion rate of 125 ml/hr.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
                <participants group_id="P2" count="161"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
                <participants group_id="P2" count="156"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>missing consent</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 318 subjects were randomized for the study but nine were excluded from analysis entirely: 3 were deemed ineligible, 5 did not have adequate documentation of informed consent, and 1 subject withdrew consent.</population>
      <group_list>
        <group group_id="B1">
          <title>D5 Lactated Ringers Solution (D5LR)</title>
          <description>IV fluid containing glucose administered throughout labor at an average infusion rate of 125 ml/hr.</description>
        </group>
        <group group_id="B2">
          <title>Lactated Ringers Solution (LR)</title>
          <description>Non-glucose IV fluid administered throughout labor at an average infusion rate of 125 ml/hr.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="153"/>
            <count group_id="B2" value="156"/>
            <count group_id="B3" value="309"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.7" spread="4.9"/>
                    <measurement group_id="B2" value="26.8" spread="4.9"/>
                    <measurement group_id="B3" value="26.8" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="156"/>
                    <measurement group_id="B3" value="309"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="275"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="256"/>
                  </measurement_list>
                </category>
                <category>
                  <title>African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>C-Section</title>
        <description>Compare c-section rates between the D5LR and LR treatment groups</description>
        <time_frame>From onset of labor to delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D5 Lactated Ringers Solution (D5LR)</title>
            <description>IV fluid containing glucose administered throughout labor at an average infusion rate of 125 ml/hr.</description>
          </group>
          <group group_id="O2">
            <title>Lactated Ringers Solution (LR)</title>
            <description>Non-glucose IV fluid administered throughout labor at an average infusion rate of 125 ml/hr.</description>
          </group>
        </group_list>
        <measure>
          <title>C-Section</title>
          <description>Compare c-section rates between the D5LR and LR treatment groups</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Regression, log binomial</method>
            <method_desc>The regression model adjusted for site of recruitment as a covariate.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
            <estimate_desc>D5LR vs. LR</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxytocin Augmentation</title>
        <description>Compare augmentation rates between the D5LR and LR treatment groups</description>
        <time_frame>From onset of labor to delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D5 Lactated Ringers Solution (D5LR)</title>
            <description>IV fluid containing glucose administered throughout labor at an average infusion rate of 125 ml/hr.</description>
          </group>
          <group group_id="O2">
            <title>Lactated Ringers Solution (LR)</title>
            <description>Non-glucose IV fluid administered throughout labor at an average infusion rate of 125 ml/hr.</description>
          </group>
        </group_list>
        <measure>
          <title>Oxytocin Augmentation</title>
          <description>Compare augmentation rates between the D5LR and LR treatment groups</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.40</p_value>
            <method>Regression, log binomial</method>
            <method_desc>The regression model adjusted for site of recruitment as a covariate.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>D5LR vs. LR</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Delivery</title>
        <description>Compare time to delivery between the D5LR and LR treatment groups</description>
        <time_frame>From onset of labor to delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>D5 Lactated Ringers Solution (D5LR)</title>
            <description>IV fluid containing glucose administered throughout labor at an average infusion rate of 125 ml/hr.</description>
          </group>
          <group group_id="O2">
            <title>Lactated Ringers Solution (LR)</title>
            <description>Non-glucose IV fluid administered throughout labor at an average infusion rate of 125 ml/hr.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Delivery</title>
          <description>Compare time to delivery between the D5LR and LR treatment groups</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" lower_limit="7.6" upper_limit="18.3"/>
                    <measurement group_id="O2" value="12.1" lower_limit="8.4" upper_limit="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>This method was used to control for site of recruitment</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From onset of labor through the mother's hospital stay</time_frame>
      <desc>Adverse event information was collected via review of medical charts.</desc>
      <group_list>
        <group group_id="E1">
          <title>D5 Lactated Ringers Solution (D5LR)</title>
          <description>IV fluid containing glucose administered throughout labor at an average infusion rate of 125 ml/hr.</description>
        </group>
        <group group_id="E2">
          <title>Lactated Ringers Solution (LR)</title>
          <description>Non-glucose IV fluid administered throughout labor at an average infusion rate of 125 ml/hr.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital anomalies</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Postpartum hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard S. Legro, M.D.</name_or_title>
      <organization>Milton S. Hershey Medical Center</organization>
      <phone>717-531-6210</phone>
      <email>rsl1@psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

